Abu Dhabi unveils CASGEVY treatment for sickle Cell and Thalassemia

The first patient is scheduled to begin therapy at Yas Clinic Hospital in April.

The Department of Health – Abu Dhabi (DoH) has announced the launch of CASGEVY, a CRISPR/Cas9 gene-editing therapy aimed at treating sickle cell disease and transfusion-dependent beta-thalassemia

The treatment is provided by Abu Dhabi Stem Cells Center, with the first patient scheduled to begin therapy at Yas Clinic Hospital in April.

The therapy extracts stem cells from a patient’s bone marrow, genetically edits them, and reimplants them into the body, according to the DoH.